Qiagen JAK2 Test Gets FDA Clearance for Additional Blood Cancer Types

Jan 23, 2018

|

NEW YORK (GenomeWeb) – Qiagen said after the close of the market on Tuesday that it received US Food and Drug Administration clearance for its Ipsogen JAK2 RGQ PCR Kit for additional use in the diagnosis of all myeloproliferative neoplasms (MPNs).

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Of Mice and Microbes

Mice in New York harbor both antibiotic-resistant bacteria and novel viruses, according to a new analysis of their fecal microbiomes.

Guidelines for Genomics in Africa

Human Heredity and Health in Africa Initiative has issued guidelines for genomic research in the region, according to Nature News.

So Many Choices

The Associated Press reports that an ethicist predicts that prenatal diagnosis and other advances will lead to more choices being available to prospective parents.

This Week in Genome Biology

In Genome Biology this week: approach to analyze alternative polyadenylation, algorithm to predict transcriptomic structural variations, and more.

Featured White Papers

Biomarker Data Management in Clinical Trials: Addressing the Challenges of the New Regulatory Landscape

Main menu